Financials in USD. Standardized financial statements.
A compact view of how Acorda Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $117.63M | $118.57M | $129.07M | $152.97M | $192.41M | $471.43M | $588.29M | $519.60M |
| Revenue Growth? | -0.8% | -8.1% | -15.6% | -20.5% | -59.2% | -19.9% | +13.2% | 0.0% |
| Cost of Revenue? | $46.05M | $61.10M | $71.55M | $64.28M | $60.48M | $99.31M | $135.71M | $108.11M |
| Gross Profit? | $71.59M | $57.47M | $57.52M | $88.69M | $131.92M | $372.12M | $452.57M | $411.49M |
| Gross Margin? | +60.9% | +48.5% | +44.6% | +58.0% | +68.6% | +78.9% | +76.9% | +79.2% |
| Operating Expenses? | $94.85M | $111.76M | $128.82M | $175.25M | $248.53M | $285.12M | $343.01M | $421.27M |
| Operating Income? | -$23.26M | -$54.29M | -$71.30M | -$86.55M | -$116.61M | $87.00M | $109.56M | -$9.78M |
| EBITDA? | -$232.82M | $27.76M | -$45.09M | -$35.80M | -$217.80M | $53.50M | -$209.46M | -$4.16M |
| Income Before Tax | -$296.02M | -$35.25M | -$109.07M | -$107.67M | -$274.25M | $20.42M | -$251.88M | -$42.27M |
| Income Tax Expense | -$43.17M | $30.67M | -$5.12M | -$8.07M | -$1.28M | -$13.26M | -$28.53M | -$6.67M |
| Net Income? | -$252.85M | -$65.92M | -$103.95M | -$99.59M | -$272.97M | $33.68M | -$223.36M | -$34.62M |
| EPS? | $-203.59 | $-66.90 | $-195.75 | $-246.40 | $-689.42 | $85.98 | $-582.69 | $-91.79 |
| Diluted EPS? | $-203.59 | $-66.90 | $-195.75 | $-246.40 | $-689.42 | $85.38 | $-582.69 | $-91.79 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality